- A joint research initiative of BADAS and Novo Nordisk Pharma (Pvt)
- Aim: To investigate the status of diabetes management, glycemic control and complications in people with diabetes in Bangladesh through web-based registry of Diabetic Association of Bangladesh (BADAS).
- Project Chairman: Prof A K Azad Khan
- Members of Starring Committee: Prof Zafar A Latif, Dr. M A Samad, Dr. Bishwajit Bhowmik, Sukanta Das
- IT support: CT Health (Farook Azam Khan)
- Target population: Patient with uncontrolled Type 2 diabetes
- Inclusion criteria: uncontrolled diabetes
- Exclusion criteria: pregnancy, intended pregnancy or breast feeding
- Study centers: 31 outpatient clinics of BADAS and its Affiliated Associations in eight (8) divisions of Bangladesh (BIRDEM, NHN (6), AAs (23), BIHS)
- Number of participants: 147000
- Status: Ongoing
- Key points:
- Mean glycated hemoglobin (HbA1c), fasting (FPG) and post prandial plasma glucose (PPG) were 9.8%, 11.4 mmol/L and 16.2 mmol/L, respectively.
- Human premixed (52.2%) and metformin (32%) were the most prescribed insulin and OADs, respectively.
- Majority of the participants (70.5%) were on single OAD and 29.5% were on ≥2 OADs.
- Among insulin recipients, 34% were on analogue insulin and penfills/ flexpens were used by 50% participants.
- Around 60% participants had one or more complications. Acute complications included hypoglycemia in 19.3% and hyperglycemia (DKA/HONK) in 4.7%.
Changing Diabetes Barometer in Bangladesh
